Systemic glucocorticosteroids have demonstrated efficacy in ulcerative colitis (UC) but cause undesired systemic side effects. Beclomethasone dipropionate (BDP) has potent topical activity and is extensively metabolized. This randomized double-blind study investigated an oral gastroresistant controlled-release preparation of BDP in 57 patients with mild to moderately severe extensive or left-sided UC. Patients were assigned to receive BDP 5 or 10 mg/d; a third group took a clinically inactive dose (1.6 g/d) of 5-aminosalicylic acid (5-ASA).
Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study / Rizzello, F; Gionchetti, P; Galeazzi, R; Novelli, G; Valpiani, D; D'Arienzo, Agesilao; Manguso, F; Castiglione, G; Varoli, G; Campieri, M.. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - ELETTRONICO. - Adv Ther. 2001 Nov-Dec;18(6):261-71.:6(2001), pp. 261-271.
Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study
D'ARIENZO, AGESILAO;
2001
Abstract
Systemic glucocorticosteroids have demonstrated efficacy in ulcerative colitis (UC) but cause undesired systemic side effects. Beclomethasone dipropionate (BDP) has potent topical activity and is extensively metabolized. This randomized double-blind study investigated an oral gastroresistant controlled-release preparation of BDP in 57 patients with mild to moderately severe extensive or left-sided UC. Patients were assigned to receive BDP 5 or 10 mg/d; a third group took a clinically inactive dose (1.6 g/d) of 5-aminosalicylic acid (5-ASA).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
